drugset / Trial / NCT00516217
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase 2
Completed
30 enrolled
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Monoclonal antibodies, such as galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This phase II trial is studying how well galiximab works in treating patients with relapsed or refractory Hodgkin's lymphoma.
Timeline
- Start
- 2008-06
- Primary completion
- 2011-09
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | galiximab | Monoclonal antibody | 500 mg/m2 | Intravenous |